AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00828243 — intervention group
Intervention type: DRUG
Intervention: Nutrient
Description: We administer stable isotopically labeled precursors of surfactant phospholipids (\[1-13C1\] acetate) and of surfactant protein-B (\[5,5,5-2H3\] leucine) to infants with neonatal respiratory distress syndrome. Using mass spectrometry, we measure incorporation of stable isotopically labeled precursors in tracheal aspirates and compare surfactant phospholipid and surfactant protein-B turnover.
Study NCT05490017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.
Study NCT05490017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
Study NCT02137863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenously 1μg/kg/10min administered just before the procedure.~1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography.
Study NCT00307502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir/ ritonavir
Description: Tipranavir: tablets 250 mg, 1000 mg/day~Ritonavir: capsules 100 mg, 400 mg/day
Study NCT02137863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % NaCl
Description: During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
Study NCT02137863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9 % NaCl
Description: During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
Study NCT02137863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % NaCl
Description: 100 ml/10min infusion just before the angiography~1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure
Study NCT00282035 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: APBI utilizing 3D-CRT radiation
Description: Accelerated partial breast irradiation utilizing 3D-CRT
Study NCT00282035 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Whole breast irradiation
Description: Whole breast irradiation
Study NCT03921749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: Both shockwave interventions will be administered without local anaesthesia. Three sessions will be administered at one-week intervals. During each session, 2000 pulses (1000 shots at the patellofemoral and tibiofemoral borders of the target knee and 1000 shots on the subchondral bone of the medial tibia condyle of the affected knee) will be delivered at 5 Hz. Energy flux density was 0.20 mJ/mm2 for patients in the focused group while radial shock waves were transmitted with 0.17 mJ/mm2 corresponding to a 3-bar energy level setting.
Study NCT03758781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX 2
Description: IRX-2 Regimen: 21 day regimen of cyclophosphamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. This 21 day regimen will be given every 12 weeks.
Study NCT03758781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg will be given via IV infusion once every 2 weeks.
Study NCT01810770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
Study NCT00308139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide, long acting release
Study NCT00308139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Study NCT03253393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Touch Technology packaging
Description: hioxifilcon A contact lens in Smart Touch Technology (hydrogel, no EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, with EDTA)
Study NCT03253393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional lens packaging
Description: hioxifilcon A contact lens in conventional lens packaging (hydrogel, no EDTA) midafilcon A contact lens in conventional lens packaging (silicone hydrogel, with EDTA)
Study NCT03253393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDTA
Description: hioxifilcon A contact lens in Smart Touch Technology (hydrogel, with EDTA) midafilcon A contact lens in Smart Touch Technology (silicone hydrogel, no EDTA)
Study NCT01889823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
Study NCT01889823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: Subjects will be breathing 100% oxygen
Study NCT01005251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesogaberan (AZD3355)
Description: 60 mg, oral, capsules, bid for 4 w
Study NCT01005251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesogaberan (AZD3355)
Description: 120 mg, oral, capsules, bid for 4 w
Study NCT01005251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesogaberan (AZD3355)
Description: 180 mg, oral, capsules, bid for 4 w
Study NCT01005251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesogaberan (AZD3355)
Description: 240 mg, oral, capsules, bid for 4 w
Study NCT01005251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral,capsules, bid for 4 w
Study NCT03446755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra uterine Cook balloon
Description: Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
Study NCT01718288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost
Description: The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2).~For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost.~The 4 groups:~1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment~1. B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment~2. A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment~2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment
Study NCT01718288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment (aspirin.....),
Description: The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.~correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids
Study NCT01718288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment (aspirin.....),
Description: The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.~correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids
Study NCT03752138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1: TK216
Description: Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.
Study NCT03752138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: TK216
Description: Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.
Study NCT03752138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Decitabine 10mg/m2
Description: 10mg/m2 by vein on Days 1-10 of a 28 day cycle.
Study NCT03752138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Decitabine 20 mg/m2
Description: 20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.
Study NCT03752138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expansion Phase TK216
Description: Expansion cohort will receive the RP2D of TK216
Study NCT03752138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expansion Phase Decitabine
Description: Expansion cohort will receive the RP2D of Decitabine
Study NCT03752138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: TK216
Description: Recommended dose from Part 1.
Study NCT03092583 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: 35 mL, 7 tubes
Study NCT03092583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 35 mL, 7 tubes
Study NCT02660788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Reminder Postcard
Study NCT02660788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Reminder Postcard
Study NCT02660788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Physician Reminder Letter
Study NCT03924622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex
Description: Mepilex Border Sacrum dressing is a multi-layered soft silicone dressing that is a recommended strategy to augment standard nursing interventions (i.e., repositioning, offloading) to prevent pressure injuries. The dressing will be placed on the sacrum.
Study NCT03924622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiquiCell
Description: LiquiCell is a thin layer of low-viscosity fluid contained in a series of bursa-like pouches. Baffles within each pouch channel the liquid to disperse pressure and the volume of liquid in the pouch is so small that there is no pressure-build up. LiquiCell is available commercially as a 36 X 18-inch mattress overlay (LiquiCell Shear Reducing Mattress Overlay) with a soft pliable top and a non-slip bottom. The overlay is positioned from the shoulders to below the hips to minimize shear.
Study NCT01466608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral administration of rosuvastatin 20 mg once daily for 21 days.
Study NCT02962700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: muscle microdialysis
Description: Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
Study NCT02962700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: muscle microdialysis
Description: Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
Study NCT01064440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose VM202
Description: Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202)
Study NCT01064440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose VM202
Description: Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 42: 4mg of VM202 (16 injections of 0.5ml of VM202)
Study NCT01064440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
Study NCT01064440 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
Study NCT03585660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic MRI
Description: Participants will be scanned using a standard clinical prostate MRI protocol.
Study NCT03585660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Prostate Biopsy
Description: Participants will undergo a prostate biopsy as their standard of care treatment. The provider performing biopsy will select areas to be biopsies as part of normal clinical judgment.
Study NCT03585660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Risk Map DSS tool
Description: The Risk Map DSS tool will select up to 2 additional areas to be biopsied based on analysis of MRI images. The clinical provider will make final decision on areas to be biopsied.
Study NCT04588246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Given PO
Study NCT04588246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04588246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04588246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04588246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04588246 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo salvage SRS
Study NCT00307502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Description: Darunavir: tablets 300 mg, 1200 mg/day~Ritonavir: capsules 100 mg, 200 mg/day
Study NCT05378230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic preparation of three Lactobacillus plantarum strains (CECT 7527, CECT 7528, CECT 7529)
Description: All subjects were submitted to 4 weeks intervention consisting on a dose-dependent regime of Lactobacillus plantarum AB-B (strains CECT 7527, CECT 7528, CECT 7529; AB-LIFE). Before starting the intervention period, all subjects were submitted to a 2-weeks run-in period. During the wash-in and intervention-periods, participants were instructed to maintain their habitual dietary habits and to continue their normal pattern of physical activity throughout the study period.~Treatments during the intervention period were: Week 1: 1 capsule/day taken during breakfast; Week 2: 2 capsules / day at- breakfast; Week 3: 2 capsules at breakfast and 1 at dinner; Week 4: 2capsules at breakfast and 2 capsules at dinner. Each capsule contains 1.2x10\^9 cfu (colony forming units) in a 1: 1: 1 ratio of the three strains.
Study NCT04588246 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo salvage SRS
Study NCT00790751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 30 minutes orally prior to initiation of sexual activity
Study NCT00790751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 30 minutes orally prior to initiation of sexual activity
Study NCT04588246 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo HA-WBRT
Study NCT03995147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles.~Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years).
Study NCT03995147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP Protocol
Description: R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab
Study NCT03851445 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Screening Platform
Description: The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
Study NCT04002141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 1 tablet oral daily
Study NCT04002141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 5mg oral daily
Study NCT01290458 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidant vitamins
Description: Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)
Study NCT01290458 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins
Description: Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)
Study NCT01028989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Reduced Glycemic Load Diet
Description: 36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load \<=46 per 1000 calories
Study NCT01028989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard Diet
Description: 25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load >=77 per 1000 calories
Study NCT03493555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Health Navigator for PrEP
Description: Peer health systems navigator to improve adherence to PrEP
Study NCT01489540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser Doppler imager (Moor)
Description: The laser Doppler imager measures the blood flow of the skin/burn
Study NCT02759757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: This is a tape that can be placed in different parts of the body using different shapes and tensions. In theory, this tape can change muscle activity.
Study NCT02759757 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A micropore tape will be used as placebo
Study NCT03992053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sacroiliac joint injection
Description: Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).
Study NCT02648204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Administered subcutaneously (s.c., under the skin) once-weekly.
Study NCT02648204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered subcutaneously (s.c., under the skin) once-weekly.
Study NCT01418144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane (TAP) block
Description: Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%
Study NCT01418144 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TAP block
Description: Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
Study NCT01533792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra/subgingival scaling using periodontal curette scraping
Description: The experimental group received supra and subgingival therapy with periodontal curettes
Study NCT01533792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supra/subgingival scaling using periodontal curette scraping
Description: The experimental group received supra and subgingival therapy with periodontal curettes
Study NCT01533792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra and subgingival scaling
Description: The experimental group received supra and subgingival scaling.
Study NCT01533792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supra and subgingival scaling
Description: The experimental group received supra and subgingival scaling.
Study NCT03192176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral Capsule
Study NCT03192176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fezolinetant
Description: Oral Capsule
Study NCT03192176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule
Study NCT01827137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galinpepimut-S
Description: Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
Study NCT01827137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: subcutaneous injection
Study NCT01827137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide
Description: adjuvant
Study NCT01827137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: optional post-ASCT therapy